Securities Class Action Filed Against Replimune Group, Inc.

Strategic Insights -

Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Key Takeaways:

  • Replimune Group, Inc. is facing a federal securities class action lawsuit alleging violations of federal securities laws.
  • The complaint claims that the Company and its executives made false and/or misleading statements and/or failed to disclose material issues related to the IGNYTE trial.
  • The trial was deemed inadequate and not well-controlled by the FDA, resulting in a Complete Response Letter from the agency.
  • Replimune common stock plummeted over 73% during intraday trading on July 22, 2025, after the company issued a press release regarding the FDA's decision.
  • The court-appointed lead plaintiff is seeking to direct and oversee the litigation on behalf of the putative class and is encouraging any member of the putative class to move the Court to serve as lead plaintiff.
  • Faruqi & Faruqi, LLP is investigating potential claims against Replimune and encouraging anyone with information regarding the company's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Statistics:

  • 73%: The percentage by which Replimune common stock plummeted during intraday trading on July 22, 2025.
  • September 22, 2025: The deadline to seek the role of lead plaintiff in the federal securities class action lawsuit.
  • 2,425,000: The number of Replimune common shares purchased or acquired by investors between November 22, 2024 and July 21, 2025.
  • $1.325: The average price of Replimune common stock during the class period (November 22, 2024 to July 21, 2025).

Sources:

  • Faruqi & Faruqi, LLP press release (August 23, 2025)
  • Newsfile Corp. (August 23, 2025)
  • Replimune Group, Inc. press release (July 22, 2025)